The global Veterinary Biologics Market , valued at US$2.61 billion in 2024, stood at US$2.72 billion in 2025 and is projected to advance at a resilient CAGR of 5.2% from 2025 to 2030, culminating in a forecasted valuation of US$3.51 billion by the end of the period. Growth in this market is mainly driven by the rising number of companion animals and pet ownership, along with increasing concerns about chronic diseases in animals. There is greater adoption of pet insurance and higher spending on animal healthcare, supported by awareness campaigns from the government and animal welfare organizations, which further boost the market growth.
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=4768999
By product type, monoclonal antibodies are expected to register a high growth rate in the veterinary biologics market, driven by their targeted mechanism of action, high efficacy, and increasing adoption in livestock health management. These biologics are increasingly used to prevent and treat specific diseases by precisely targeting pathogens or toxins, offering a more selective and effective alternative to traditional therapies such as antibiotics. In livestock applications, monoclonal antibodies are particularly valuable for conditions that require rapid immune support, leading to reduced morbidity and improved productivity. Their use supports the global shift toward sustainable animal farming practices and the reduction of antimicrobial resistance (AMR), positioning them as a preferred choice in advanced biologic interventions.
By application, the dermatology segment is projected to hold the largest share in the veterinary biologics market due to the increasing prevalence of skin disorders in companion and livestock animals, such as allergies, bacterial and fungal infections, and parasitic infestations. Rising pet ownership and greater awareness about animal health are fueling demand for advanced biologics, including vaccines, immunotherapies, and monoclonal antibodies for dermatological issues. Innovations in biologics that provide long-lasting efficacy with minimal side effects further promote adoption. Additionally, higher healthcare spending on animals, along with the expansion of veterinary clinics and hospitals, contributes to this segment’s growth. The availability of targeted biologics for chronic skin conditions is also expected to improve treatment outcomes. All these factors collectively establish dermatology as the leading application segment in the veterinary biologics market.
By geography, the region’s rapid market growth is due to the increasing pet population, heightened awareness of animal health, and higher spending on veterinary care. Also, advanced veterinary healthcare infrastructure and the presence of key market players are further boosting growth in countries such as China, India, and Japan. Livestock farming also significantly contributes to the region’s economy. Countries such as India and China have large numbers of livestock animals, driven by the rising demand for meat, milk, and other animal-based products.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=4768999
Prominent players in the veterinary biologics market are Zoetis Services LLC (US), IDEXX (US), Elanco (US), Merck & Co., Inc. (US), Thermo Fisher Scientific Inc. (US), Boehringer Ingelheim International GmbH (Germany), Neogen Corporation (US), Bio-Rad Laboratories, Inc. (US), ImmuCell Corporation (US), and Innovative Diagnostics (France).
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/veterinary-biologics-market-4768999.html